Tiragolumab Disappoints in Untreated Advanced HCC – Medscape

Written by

admin

in

  1. Tiragolumab Disappoints in Untreated Advanced HCC  Medscape
  2. TRIPLET-HCC at ESMO 2025: Adding Ipilimumab to Atezolizumab–Bevacizumab Fails to Improve Outcomes in Unresectable HCC  Oncodaily
  3. ESMO 2025: Roche’s TIGIT failures continue, this time in liver cancer  Yahoo
  4. Tiragolumab Regimen Misses PFS End Point in Hepatocellular Carcinoma  CancerNetwork

Continue Reading

More posts